Articles

Videos

Podcasts

Clinical

David DeRemer, PharmD, BCOP, FCCP, FHOPA, a past-president on the board of Hematology/Oncology Pharmacy Association (HOPA), discusses why a greater focus on colorectal cancer screening was important to highlight at the HOPA 2022 annual conference.

HOPA Past President: Research Assessing the Microbiome in Colorectal Cancer Is Emerging Daily, May Have Significant Impact to the Field

Bevacizumab-maly (Almysys; mAbxience) is the third biosimilar of bevacizumab (Avastin) approved in the United States.

Third Biosimilar to Bevacizumab Granted FDA Approval

Encorafenib in combination With anti-EGFR monoclonal antibody improves overall survival.

BRAF Inhibition Offers New Standard of Care in for Colorectal Cancer

Ramucirumab (Cyramza; Eli Lilly) is FDA-approved for 5 unique cancer indications. 

Oncology Overview: Examining the Clinical Utility of Ramucirumab Targeted Therapy 

The CAR T-cell therapy CYAD-101 was being evaluated in combination with FOLFOX followed by pembrolizumab (Keytruda) in patients with unresectable metastatic colorectal cancer.

Clinical Hold Placed on Trial of CAR T-Cell Therapy for Metastatic Colorectal Cancer

Culturally tailored patient navigation can improve underserved individuals’ health literacy, trust in the health care system, and use of cancer screening tools, study results show.

Program May Boost Colorectal Screenings for Hispanic Adults and Reduce Gender Disparities

Christopher Mast, MD, vice president of clinical informatics at Epic, explains his outlook for the future in the field of oncology in light of the ongoing delays in cancer screenings rates.

How Pharmacists Can Help Address Ongoing Delays in Cancer Screenings

Christopher Mast, MD, vice president of clinical informatics at Epic, explains the level to which cancer screening rates would need to rise to meet pre-pandemic rates.

The Impact of Ongoing Delays in Cancer Screenings in 2021 on Patient Health, Health Systems

Commonly used medications may influence responses to checkpoint inhibitors among patients with cancer.

Antihistamines Associated With Improved Immunotherapy Response in Patients With Cancer

The FDA initially approved regorafenib for chemorefractory metastatic colorectal cancer and unresectable gastrointestinal stromal tumor in 2012.

Oncology Overview: Regorafenib For Metastatic Colorectal Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma

® Colorectal Cancer Resource Center is a comprehensive resource for clinical news and expert insights on cancers that start 